{"url_path":"/sec/biaf/8-k/2026-09-11/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-09-11","source_url":"https://www.sec.gov/Archives/edgar/data/1712762/0001493152-26-042304-index.html","accession_number":"0001493152-26-042304","cik":"0001712762","ticker":"BIAF","issuer_name":"bioAffinity Technologies, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1712762/0001493152-26-042304-index.html","primary_entity_key":"0001712762","primary_entity_name":"bioAffinity Technologies, Inc."},"word_count":182,"has_tables":true,"body_markdown":"**Item\n7.01. Regulation FD Disclosure.**\n\n \n\nbioAffinity\nTechnologies, Inc., a Delaware corporation, (the “Company”) has prepared presentation materials (the “Presentation\nMaterials”) that management intends to use from time to time in presentations about the Company’s operations and performance,\nincluding at the H.C. Wainwright 28th Annual Global Investment Conference being held September 14, 2026, through September 16, 2026.\nThe Presentation Materials are furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\n \n\nThe\ninformation in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K are furnished and shall not be deemed to be “filed”\nfor the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject\nto the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be\nincorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after\nthe date of this Current Report, regardless of any general incorporation language in any such filing."}